NASDAQ · LNTH
Lantheus Holdings, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$100.46▲ 0.14% ($0.14)at close
As of 4:00 PM ET
Valuation
Revenue & margin DCF
Verdict: cheap. Price below all scenarios.
The price needs 2.8% revenue growth a year for 10 years. Our scenarios assume 9.0–15.6%.
That's below its past 4-year pace of 38.0%.
Value per share
Base case
$223.07
Price used $100.46 is 55% below this
USD · TTM ending Jun 30, 2026 · Price Oct 30, 8:00 PM UTC
Revenue each value needs
Revenue today $1.6B. The price needs $2B by 2036. Base case: $5.1B. At its recent pace: $39B. Bear to Bull: $3.7B to $6.7B.
Revenue today $1.6B. The price needs $2B by 2036. Base case: $5.1B. At its recent pace: $39B. Bear to Bull: $3.7B to $6.7B.
Revenue in 2036
today $1.6B
−$3Bless than the Base case
Value per share · Base case
$223.07
Price $100.46
55% below this
- 10-yr revenue CAGR
- 12.5%
- Ending operating margin
- 19.4%
- Discount rate
- 6.7%
USD · TTM ending Jun 30, 2026 · Price Oct 30, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 81.04% over the last year. Revenue grew 2.35% over the trailing twelve months. Operating margin moved from 28.78% to 19.43%. Free cash flow declined 17.63% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 19.43%. A decisive move in revenue — currently up 2.35% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
10
Buy
9
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 5, 2026
Q3 FY26 · EPS est $1.24 · Revenue est $360.1M
Same quarter, year over year
FY26 YTD -2.9%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $3.01 vs $3.10 · 0 of 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $6.04
- -10.9%
- FY24
- $6.78
- —
Q2 FY26
Reported Aug 6, 2026 · Latest
HoverTap a cell to inspect
Actual
$1.55
Estimate
$1.30
Year over year
-1.3%
Vs prior quarter
+6.2%
Institutional Sentiment
Lantheus Holdings, Inc. · LNTH
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.